You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 195961 - 195970 of 207725 results
  1. Preventing Burn Wound Infection Using a Novel Free Radical Sterilization System

    SBC: GOLKOWSKI CZESLAW            Topic: NIAID

    DESCRIPTION (provided by applicant): Approximately two million burn injury cases require medical attention on a yearly basis in the United States alone, with 20,000 of these cases requiring admission to specialized burn centers. One of the foremost causesof morbidity and mortality in the burn patient is infection. Indeed, for those patients with burn size greater than 40% of total body surface are ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. A transfollicular nanovaccine against leishmaniasis

    SBC: VINDICO NANOBIOTECHNOLOGY, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The World Health Organization estimates that over 350 million people are at risk of developing leishmaniasis and infection prevalence is 14 million people in the world. Annually, 2 million people are infected with Leishmania species and 270,000 will die. Leishmaniasis is one of the most important parasitic diseases affecting the U.S. military today, with over 2 ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Metallo-beta-lactamase Inhibitors

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): -lactam resistance conferred by zinc-based metallo- -lactamases (Amber Class B) is an emerging global health problem1-3. Members of this family of enzymes such as NDM-1 are found on mobile genetic elements which are rapidly spreading in Enterobacteriaceae and threaten to erode the future utility of the - lactam antibiotics (i.e. penicillins, cephalosporins, c ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic Antibodies for Rabies

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody to Respiratory Syncytial Virus (RSV) that is now bein ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic Antibodies for Bacteria

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody to Respiratory Syncytial Virus (RSV) that is now bein ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Preserving beta-lactam utility against pathogens producing all classes of beta-la

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): This Phase I SBIR Grant focuses on advancement of a new class of inhibitors of serine-based b-lactamases (Ambler classes A, C and D), for combination with the only subclass of b-lactams (the monobactams) that are not sensitive to zinc-based enzymes (Ambler Class B). Full coverage against all classes of b-lactamases is critically important in light of the alarmi ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity

    SBC: IMMURX LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): We have discovered, characterized and functionally defined a novel, immune inhibitory ligand. This ligand is hematopoietically-expressed, a distant member of the B7 Ig-superfamily, and its extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Distinct fr ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid Response Vaccines for Botulinum Neurotoxins

    SBC: Iterative Therapeutics Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currentlyavailable pentavalent toxoid vaccine requires multiple boosters before being effective, and protects unequally against the different BoNT serotyp ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. A Rapid Point-of-care Diagnostic for Neisseria gonorrhoeae STDs

    SBC: NetBio, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Improved diagnosis of Neisseria gonorrhoeae (GC) infections represents a critical unmet medical need. The CDC estimates that approximately 700,000 people are infected by GC annually, with approximately half of these cases reported. The clinical spectrum of GC infection includes urethritis and cervicitis, pelvic inflammatory disease (PID), and disseminated disea ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Human Ghrelin As An Effective Mitigator of Acute Radiation Injury

    SBC: THERASOURCE, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): This SBIR Phase I proposal is intended to demonstrate the feasibility of developing a novel and effective therapeutic approach that can save lives of people with radiation injury. Acute radiation injury may occur in various incidents as well as the terrorist radiation exposure scenario. Acute radiation syndrome develops after whole-body or a partial-body irradi ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government